Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
800000 participants
OBSERVATIONAL
2021-10-09
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-COPD high-risk population
The local residents gain a COPD-SQ score \< 16.
Comprehensive intervention and management Ⅰ
Mainly health advisory.
COPD high-risk population
The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 either with or without bronchodilator administration.
Comprehensive intervention and management Ⅱ
Health advisory and regular follow-ups.
Confirmed COPD patients
The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 after administration of bronchodilators.
Comprehensive intervention and management Ⅲ
Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Comprehensive intervention and management Ⅰ
Mainly health advisory.
Comprehensive intervention and management Ⅱ
Health advisory and regular follow-ups.
Comprehensive intervention and management Ⅲ
Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* residents living in the survey area with more than 6 months in the past year.
Exclusion Criteria
* experienced severe cardiac insufficiency, severe arrhythmia or unstable angina pectoris in the past 4 weeks;
* experienced massive hemoptysis in the past 4 weeks;
* received chest, abdominal or ophthalmic surgery in the past 3 months;
* have mental disorders (e.g. auditory hallucinations, visual hallucinations, taking antipsychotics, seizures requiring medication, etc.);
* have cognitive impairment (e.g. dementia, comprehension impairment, etc.);
* have uncontrolled hypertension (i.e. systolic blood pressure \> 200 mmHg, diastolic blood pressure \> 100 mmHg);
* present with heart rate \>120 beats/min;
* have aortic aneurysm;
* have severe hyperthyroidism;
* are pregnant or lactating women;
* experienced respiratory infectious diseases (e.g. tuberculosis, influenza, etc.) in the past month.
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China-Japan Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ting YANG
Prof.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ting YANG, M.D.
Role: PRINCIPAL_INVESTIGATOR
China-Japan Friendship Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China-Japan Friendship Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ke HUANG, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-145-K103
Identifier Type: -
Identifier Source: org_study_id